"covid-19" prototype MTF clinical trial
Active Other Transaction Agreement Awarded Last action
- Contract number
- W911QY2090024
- Awardee
-
Allucent Government Services (Us) LLC UEI C7DJDL6EZT94
- Awarding agency
-
ACC Aberdeen Proving Ground
Army Contracting Command, Department of Defense
- Obligated
- $35,974,178
Award facts
- Contract value 67% obligated
-
- $35,974,178.00 Current, with exercised options
- $54,004,136.00 Potential, with all options
- Completion date 97% complete
- Current and potential, with all options
- Contracting staff
- Funding agency
- Joint PEO Chemical and Biological Defense Acquisition Support Center, Department of Defense
- NAICS code
- Not on record
- Competition
- Competed Program Solicitation
- Pricing
- Other
- Place of performance
- Houston, TX 77060, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $6,525,367 | |
| Funding Only Action | $10,974,406 | |
| Supplemental Agreement for work within scope | -$7,055,552 | |
| Supplemental Agreement for work within scope | $7,500,000 | |
| Original award | $18,029,957 |
Show all 12
About this award
The U.S. Army's Joint Program Executive Office for Chemical and Biological Defense awarded an Other Transaction Agreement valued at $54 million to Allucent Government Services (US) LLC on August 17, 2020, for a COVID-19 prototype military treatment facility clinical trial under Operation Warp Speed. The contract is being performed in Houston, Texas, and is scheduled for completion by December 31, 2026. Allucent Government Services, formerly known as Pharm-Olam LLC, is a clinical research organization specializing in comprehensive clinical trial services and medical countermeasure development for federal agencies, with particular expertise in infectious disease research and pandemic preparedness.
This award reflects Allucent's established capabilities in executing clinical trials across all development phases and managing complex federal medical research initiatives. The contractor holds substantial existing federal vehicles, including a $550 million indefinite delivery contract with the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response for clinical trial planning and execution services, as well as a $346.6 million multiple-award contract under the National Institutes of Health's Early Phase Clinical Trial Units program. The contract does not include a set-aside designation, and Allucent's experience supporting both Defense Department and civilian health agencies positions it as a key partner in the federal government's response to emerging infectious disease threats.
Quick answers
Who was awarded contract W911QY2090024?
W911QY2090024 was awarded to Allucent Government Services (Us) LLC by ACC Aberdeen Proving Ground (Army Contracting Command) on August 17, 2020.
How much is contract W911QY2090024 worth?
The government has obligated $35,974,178 on W911QY2090024. Its potential value, with all options, is $54,004,136.
Which agency awarded contract W911QY2090024?
ACC Aberdeen Proving Ground (Army Contracting Command) awarded W911QY2090024, with funding from Joint PEO Chemical and Biological Defense (Acquisition Support Center).
Was contract W911QY2090024 competed?
The extent of competition for W911QY2090024 was competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award